Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF
Sandi Radko-Juettner(St. Jude Children's Research Hospital), Charles W.M. Roberts(Harvard University), Eric S. Fischer(Dana-Farber Cancer Institute), Zhiping Wu(St. Jude Children's Research Hospital), Katherine A. Donovan(Harvard University), Shondra M. Pruett‐Miller(St. Jude Children's Research Hospital), Shourya S. Roy Burman(Harvard University), Nathanael S. Gray(Stanford University), Nada Mageed(Harvard University), Behnam Nabet(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Robert J. Mobley(St. Jude Children's Research Hospital), Priya Mittal(St. Jude Children's Research Hospital), Raymond D. Carter(St. Jude Children's Research Hospital), Scott A. Brown(St. Jude Children's Research Hospital), Moritz Hunkeler(Harvard University), Hong Yue(Harvard University), Anna M. Schmoker(Harvard University), Zhexin Zhu(National Science Centre), Wojciech Rosikiewicz(St. Jude Children's Research Hospital), Jacquelyn Myers(University of Rochester), Meghan McReynolds(St. Jude Children's Research Hospital), Elizabeth Stewart(St. Jude Children's Research Hospital), Janet F. Partridge(St. Jude Children's Research Hospital), Baranda S. Hansen(St. Jude Children's Research Hospital), Alexis Robertson(St. Jude Children's Research Hospital), Junmin Peng(St. Jude Children's Research Hospital)
Cited by 59
Related Papers
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
|Journal of Biological Chemistry|2009|1.8k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848
Toward understanding and exploiting tumor heterogeneity
|Nature Medicine|2015|770